DENTSPLY SIRONA Inc. (NASDAQ:XRAY) was upgraded by analysts at Barrington Research from a “market perform” rating to an “outperform” rating in a research report issued to clients and investors on Monday, November 6th, Marketbeat Ratings reports. The brokerage currently has a $73.00 price objective on the medical instruments supplier’s stock. Barrington Research’s target price would suggest a potential upside of 8.13% from the company’s current price. Barrington Research also issued estimates for DENTSPLY SIRONA’s Q1 2018 earnings at $0.62 EPS, Q2 2018 earnings at $0.71 EPS, Q3 2018 earnings at $0.76 EPS, Q4 2018 earnings at $0.85 EPS, FY2018 earnings at $2.95 EPS and FY2019 earnings at $3.35 EPS.
XRAY has been the topic of several other reports. BidaskClub lowered shares of DENTSPLY SIRONA from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 16th. Zacks Investment Research upgraded shares of DENTSPLY SIRONA from a “sell” rating to a “hold” rating in a report on Friday, October 20th. Cleveland Research downgraded shares of DENTSPLY SIRONA from a “buy” rating to a “neutral” rating in a research report on Thursday, October 5th. Credit Suisse Group reissued an “outperform” rating and set a $75.00 target price (up previously from $67.00) on shares of DENTSPLY SIRONA in a research report on Thursday, July 13th. Finally, UBS AG reissued a “neutral” rating and set a $59.00 target price (down previously from $62.00) on shares of DENTSPLY SIRONA in a research report on Thursday, August 10th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. DENTSPLY SIRONA has an average rating of “Hold” and a consensus price target of $67.00.
Shares of DENTSPLY SIRONA (NASDAQ XRAY) opened at $67.51 on Monday. DENTSPLY SIRONA has a 1 year low of $52.53 and a 1 year high of $67.95. The company has a quick ratio of 1.59, a current ratio of 2.32 and a debt-to-equity ratio of 0.21. The company has a market cap of $15,524.27, a PE ratio of 26.93, a P/E/G ratio of 2.68 and a beta of 1.27.
In related news, Director Francis J. Lunger sold 8,900 shares of DENTSPLY SIRONA stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $65.90, for a total transaction of $586,510.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Nicholas W. Alexos purchased 50,000 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The stock was bought at an average cost of $65.85 per share, for a total transaction of $3,292,500.00. The disclosure for this purchase can be found here. 1.99% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in DENTSPLY SIRONA by 2.5% during the 2nd quarter. Vanguard Group Inc. now owns 22,728,062 shares of the medical instruments supplier’s stock worth $1,473,688,000 after acquiring an additional 562,993 shares during the period. Ruane Cunniff & Goldfarb Inc. boosted its position in DENTSPLY SIRONA by 0.5% during the 3rd quarter. Ruane Cunniff & Goldfarb Inc. now owns 8,890,655 shares of the medical instruments supplier’s stock worth $531,750,000 after acquiring an additional 40,767 shares during the period. Principal Financial Group Inc. boosted its position in DENTSPLY SIRONA by 6.7% during the 3rd quarter. Principal Financial Group Inc. now owns 6,910,770 shares of the medical instruments supplier’s stock worth $413,333,000 after acquiring an additional 436,338 shares during the period. Jackson Square Partners LLC lifted its holdings in shares of DENTSPLY SIRONA by 15.6% during the 3rd quarter. Jackson Square Partners LLC now owns 6,334,906 shares of the medical instruments supplier’s stock valued at $378,890,000 after buying an additional 855,199 shares during the last quarter. Finally, Veritas Asset Management LLP lifted its holdings in shares of DENTSPLY SIRONA by 2.6% during the 2nd quarter. Veritas Asset Management LLP now owns 6,201,155 shares of the medical instruments supplier’s stock valued at $402,083,000 after buying an additional 157,616 shares during the last quarter. 94.68% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by BBNS and is owned by of BBNS. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://baseballnewssource.com/markets/dentsply-sirona-inc-xray-upgraded-to-outperform-at-barrington-research/1762598.html.
About DENTSPLY SIRONA
DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.
Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with our FREE daily email newsletter.